Market Overview

Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'

Share:

Canadian biotech Zymeworks Inc. (NYSE: ZYME) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, leading to a more bullish stance on the company’s stock from Raymond James.

The Analyst

Raymond James analyst David Novak upgraded Zymeworks from Outperform to Strong Buy while upping the target price from $36 to $40.

The Thesis

The new data presented at the ESMO conference demonstrates Zymeworks "was born to run," Novak wrote in a note.

The Vancouver-based biotech’s latest results, demonstrating what Novak called “highly encouraging antitumor activity,” could be a major step forward, he said, with the potential to “in time, transform the HER2 therapeutic landscape.

“With multiple potential clinical catalysts anticipated in the coming months, we expect additional positive data readouts, and thus are upgrading ZYME to a Strong Buy,” Novak wrote.

Price Action

Zymeworks shares traded around $24.79 at publication time.

Related Links:

The Week Ahead In Biotech: Conference Presentations, IPOs Hit Top Gear

The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study

Latest Ratings for ZYME

DateFirmActionFromTo
Oct 2019MaintainsBuy
Sep 2019UpgradesOutperformStrong Buy
Aug 2019Initiates Coverage OnBuy

View More Analyst Ratings for ZYME
View the Latest Analyst Ratings

Posted-In: David Novak ESMOAnalyst Color Biotech Upgrades Price Target Analyst Ratings General

 

Related Articles (ZYME)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
WBCLSADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Stocks That Hit 52-Week Highs On Tuesday

Lamb Weston Q1 Earnings Preview